Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
16 February 2015
|
| In: |
European journal of cancer
Year: 2015, Jahrgang: 51, Heft: 5, Pages: 569-576 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2015.01.059 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2015.01.059
|
| Verfasserangaben: | Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, Michael Pohl, Peter Thuss-Patience, Florian Bassermann, Ulrike Helbig, Florian Weißinger, Elisabeth Schnoy, Klaus Becker, Gertraud Stocker, Josef Rüschoff, Andreas Eisenmenger, Irini Karapanagiotou-Schenkel, Florian Lordick |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1547499583 | ||
| 003 | DE-627 | ||
| 005 | 20220813054438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 160927s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2015.01.059 |2 doi | |
| 035 | |a (DE-627)1547499583 | ||
| 035 | |a (DE-576)477499589 | ||
| 035 | |a (DE-599)BSZ477499589 | ||
| 035 | |a (OCoLC)1340931544 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lorenzen, Sylvie |d 1973- |e VerfasserIn |0 (DE-588)128891106 |0 (DE-627)384629202 |0 (DE-576)297385739 |4 aut | |
| 245 | 1 | 0 | |a Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer |b a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie |c Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, Michael Pohl, Peter Thuss-Patience, Florian Bassermann, Ulrike Helbig, Florian Weißinger, Elisabeth Schnoy, Klaus Becker, Gertraud Stocker, Josef Rüschoff, Andreas Eisenmenger, Irini Karapanagiotou-Schenkel, Florian Lordick |
| 264 | 1 | |c 16 February 2015 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.09.2016 | ||
| 700 | 1 | |a Haag, Georg Martin |d 1979- |e VerfasserIn |0 (DE-588)133390934 |0 (DE-627)544043863 |0 (DE-576)29981548X |4 aut | |
| 700 | 1 | |a Eisenmenger, Andreas |e VerfasserIn |0 (DE-588)1114766054 |0 (DE-627)869048333 |0 (DE-576)477499805 |4 aut | |
| 700 | 1 | |a Karapanagiotou-Schenkel, Irini |e VerfasserIn |0 (DE-588)1101472952 |0 (DE-627)859729141 |0 (DE-576)469905905 |4 aut | |
| 700 | 1 | |a Lordick, Florian |d 1966- |e VerfasserIn |0 (DE-588)114389349 |0 (DE-627)52295085X |0 (DE-576)289795567 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 51(2015), 5, Seite 569-576 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie |
| 773 | 1 | 8 | |g volume:51 |g year:2015 |g number:5 |g pages:569-576 |g extent:9 |a Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2015.01.059 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20160927 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 114389349 |a Lordick, Florian |m 114389349:Lordick, Florian |d 50000 |e 50000PL114389349 |k 0/50000/ |p 15 |y j | ||
| 998 | |g 1101472952 |a Karapanagiotou-Schenkel, Irini |m 1101472952:Karapanagiotou-Schenkel, Irini |d 910000 |e 910000PK1101472952 |k 0/910000/ |p 14 | ||
| 998 | |g 1114766054 |a Eisenmenger, Andreas |m 1114766054:Eisenmenger, Andreas |d 910000 |e 910000PE1114766054 |k 0/910000/ |p 13 | ||
| 998 | |g 133390934 |a Haag, Georg Martin |m 133390934:Haag, Georg Martin |d 910000 |d 910100 |e 910000PH133390934 |e 910100PH133390934 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1547499583 |e 2939603073 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1547499583","note":["Gesehen am 27.09.2016"],"name":{"displayForm":["Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, Michael Pohl, Peter Thuss-Patience, Florian Bassermann, Ulrike Helbig, Florian Weißinger, Elisabeth Schnoy, Klaus Becker, Gertraud Stocker, Josef Rüschoff, Andreas Eisenmenger, Irini Karapanagiotou-Schenkel, Florian Lordick"]},"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"16 February 2015"}],"language":["eng"],"id":{"eki":["1547499583"],"doi":["10.1016/j.ejca.2015.01.059"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"pubHistory":["28.1992 -"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"recId":"266883400","disp":"Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer a randomised phase II trial of the Arbeitsgemeinschaft Internistische OnkologieEuropean journal of cancer","part":{"extent":"9","year":"2015","issue":"5","volume":"51","text":"51(2015), 5, Seite 569-576","pages":"569-576"},"titleAlt":[{"title":"EJC online"}],"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"id":{"eki":["266883400"],"zdb":["1468190-0"],"issn":["1879-0852"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"person":[{"display":"Lorenzen, Sylvie","family":"Lorenzen","given":"Sylvie","role":"aut"},{"role":"aut","given":"Georg Martin","display":"Haag, Georg Martin","family":"Haag"},{"given":"Andreas","family":"Eisenmenger","display":"Eisenmenger, Andreas","role":"aut"},{"role":"aut","family":"Karapanagiotou-Schenkel","display":"Karapanagiotou-Schenkel, Irini","given":"Irini"},{"display":"Lordick, Florian","family":"Lordick","given":"Florian","role":"aut"}],"title":[{"title_sort":"Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer","subtitle":"a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","title":"Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer"}],"physDesc":[{"extent":"9 S."}]} | ||
| SRT | |a LORENZENSYLAPATINIBV1620 | ||